8:00 am Registration Opens & Coffee Welcome

Chair Day One: Boris Minev

Progressing Early Discovery Through to Pre-Clinical: Emerging Research & Optimized Novel Viruses

9:00 am Overview of CF33 Vaccinia Oncolytic Virus Platform


  • Scientific review of the CF33 OV platform
  • Clinical development overview of CF33, checkvacc (CF33-PDL1), and onCARlytic (CF33-CD19)
  • Future development of the OV platform

9:30 am Outlining an iTANK Technology Platform & ELC-201 Promising Therapeutic Efficacy

  • Di Yu Head of Translational Research, Elicera Therapeutics


  • iTANK is a technology platform that allows us to arm oncolytic virus or CAR-T cells with a pluripotent immunomodulating factor, NAP
  • Elicera’s drug candidate ELC-201 is an iTANK-engineered oncolytic virus further armed to express 4-1BBL
  • ELC-201 exhibits promising therapeutic efficacy against pancreatic cancer in murine model, and induces bystander immune activation by altering the immunosuppressive tumor microenvironment

10:00 am Controlling Oncolytic Virus Growth & Gene Expression With Small Molecules

  • John Bell Senior Scientist, Ottawa Hospital Research Institute


  • Vaccinia virus has simple promoter structures and is amenable to modulation with transgenic genetic control elements
  • Synthetic virology strategies can be used to design externally regulated virus promoters
  • In mouse models, virus replication and/or transgene expression can be modulated using FDA approved small molecules

10:30 am Development of Robust Real-Time Potency Assays for Oncolytic Viruses: From Discovery to Manufacturing

  • Yama Abassi Associate Vice President of New Market Development, Agilent Technologies


  • Challenges with existing potency assays for oncolytic viruses
  • Provide a technical overview of real-time potency assays for oncolytic viruses
  • Discuss quantitative parameters of real-time potency assays for oncolytic viruses
  • Combining real-time imaging together with impedance biosensors for
    assessment of potency of oncolytic viruses

11:00 am Morning Break & Speed Networking

Novel Combination Therapies to Maximize Anti-Cancer Effectiveness

12:00 pm Clinical Efficacy & Immune Activation Demonstrated By Oncolytic Adenovirus ONCOS-102 In Solid Tumors


  • Robust clinical activity of ONCOS-102 in combination with both anti-PD1 and chemotherapy has been observed in several solid tumor types
  • ONCOS-102 drives broad and persisting immune responses in responding patients
  • Extended dosing regimen drives stronger immune activation and increased systemic activity

12:30 pm Manufacturing Pathways Supporting use of Viral Vectors for Oncological Indications

  • Ian Goodwin Associate Director, Program Design, FUJIFILM Diosynth Biotechnologies


  • Oncolytic virotherapy brings both common and unique challenges with regards to virus-specific process, analytical, and quality considerations that must be overcome to support successful transition from lab to clinic
  • The challenges discussed today will focus on these key areas, drawing from both experience and forward-looking innovation pathways to reduce the cost and time from lab to GMP to clinic

1:00 pm CG0070 for Bladder Cancer


  • The data on CG0070 for NMIBC as a single agent will be reviewed
  • The data on CG0070 in combination with pembrolizumab for NMIBC will be reviewed
  • The data on CG0070 plus nivolumab for MIBC will be reviewed

1:30 pm Designing the Best Partner in Crime for Cancer Therapy


  • Introducing an oncolytic virus engineered to enhance replication and heat up the tumor microenvironment can overcome challenges facing cancer immunotherapeutics
  • The choice of transgenes for the oncolytic virus should depend on the combination agent to demonstrate synergy and potentiate overall therapeutic effect
  • HSV-1’s high payload capacity allows testing for different combination strategies within a single system, pushing the boundaries to explore monotherapy potential

2:00 pm Lunch Break & Networking

3:00 pm Development & in Large Scale Oncolytic Virus Production


  • Large scale oncolytic virus production practices for clinical supply
  • Process development and manufacturing using fixed bed bioreactor technologies
  • Process development and manufacturing using dissolvable porous microcarrier technologies

3:30 pm

Interactive Roundtable Discussions

OV Selection & Combination Therapy Considerations

Should we be selecting an appropriate type of OV depending on the specific combination strategy for each patient?

This roundtable will aim to discuss what combinations might be more effective with genetically simple and pro-inflammatory viruses, and conversely more complex and slower-replicating viruses.

Austin Nuschke
Senior Medical Scientist, Solid Tumor Oncology, Amgen

Conventional Cancer Treatments to Enhance Anti-Tumour Immune Activation

Are radiotherapy and chemotherapy viable options to combine with OV?

This roundtable will aim to discuss how the OV-combined tumor immunotherapy can be
enhanced according to the tumor location and individual patient progress.

Bart Spiesschart
Principal Scientist, In Vivo Pharmacology, Boehringer Ingelhiem


Expanding Our Knowledge of OV-specific Biomarkers

Can OV-combined immunotherapy be better controlled and improved?

With biomarkers such as MSI, TMB, and PD-L1 being used successfully to predict and monitor PD-1 blockade therapy, this roundtable will aim to discuss how these biomarkers can be evaluated and how best we can pursue other novel OV-specific biomarkers to improve OV-combined immunotherapy.

Francesca Barone
Chief Scientific Officer, Candel Therapeutics


4:15 pm Afternoon Break & The Oncolytic Virotherapy Innovation Showcase


Back for its second year, the Oncolytic Virotherapy Summit’s Innovation is back! With an ever increasing number of OV biotech’s and start-ups filing for IPO and looking to form licensing agreements or collaborations with larger institutions, the 7th Oncolytic Virotherapy Summit will once again host an innovation showcase aiming to demonstrate some of the latest innovations from the field, where emerging oncolytic virus start-ups and emerging companies with an active drug-discovery pipeline will pitch and present their company to the entire audience, demonstrating the opportunity they can bring to market.

The 10 finalists will be hand-picked by our prestigious selection committee, and on the day of the event the committee will select one company to receive the Oncolytic Virotherapy Summit’s Innovation Award.


To Apply For The Innovation Showcase, Submit Your Application Here

Translational Insights & Biomarker Analysis in Clinical Trials

4:45 pm A Landscape Analysis of Oncolytic Viruses


  • An overview of the current preclinical and clinical landscape of oncolytic viruses
  • Present trends and advancements within the field, including combination approaches within the clinic and modifications to improve the efficacy of the therapies
  • Potential future directions of the OV space

5:15 pm The Codon-Modified Virotherapeutic Codalytic™ Modulates The Tumor Microenvironment In Models With Different Immune Contextures


  • Overview of Codagenix’s codon-modification platform and the design of CodaLytic
  • Changes in the tumor microenvironment induced by CodaLytic, alone or in combination with checkpoint inhibitors, in murine models and a human tumor explant system
  • Connection to efficacy outcomes, incl. tumor growth, survival and cytotoxicity

5:45 pm VET3-TGI, An Oncolytic Vaccinia Targeting TGF-Beta

  • Steve Thorne Chief Scientific Officer, Kalivir Immunotheraputics


  • TGF-beta inhibition is a potentially powerful approach to cancer therapy
  • Oncolytic viral expression of a TGF-beta inhibitor overcomes many of the limitations of existing therapies
  • Development of a multi-mechanistic oncolytic virus incorporating a TGF-beta inhibitor results in a potent pre-clinical cancer therapy

6:45 pm End of Conference Day One